Today we come to you with a special literature blog post highlighting 10 key deprescribing articles that together provide an overview of the field of deprescribing – covering the mindset of deprescribing, the complexity of and challenges related to deprescribing in clinical practice, the development and testing of deprescribing interventions, and perspectives of future deprescribing research. We believe each of these 10 articles offer important insights or findings related to deprescribing.
The list is based on careful deliberation between the two of us, after considering a number of worthy candidates. Of course, this list is based on our opinion only and we limited ourselves to 10 articles (which wasn’t easy at all!). We would love to hear your input on our list, so let us know if we have missed any important papers or topics. We will then follow up with a complete list of recommended deprescribing articles for use of all deprescribers out there!
Previous studies have found an association between aggressive cancer care and lower quality end of life. Despite international recommendations, late or very late referral to palliative care seems frequent. This study aimed to evaluate the association between the duration of involvement of a palliative care team (PCT), and aggressive cancer care, and to identify factors associated with aggressive cancer care.
Early provision of palliative care, at least 3–4 months before death, can improve patient quality of life and reduce burdensome treatments and financial costs. However, there is wide variation in the duration of palliative care received before death reported across the research literature. This study aims to determine the duration of time from initiation of palliative care to death for adults receiving palliative care across the international literature.
How is palliative care being delivered to patients with noncancer illness (ie, chronic organ failure and dementia), and is it being delivered differently than for patients with cancer?
Question What is the effect of integrated palliative and oncology care (IPC) on patient-reported and end-of-life (EOL) outcomes for patients with acute myeloid leukemia (AML)?
Este sitio web utiliza cookies propias y de terceros para analizar el tráfico de la red, así como poder personalizar la información que ofrece a sus usuarios o promover sus servicios. Información para cambiar esta configuración en el botón "Ver preferencias".
Funcional
Siempre activo
El almacenamiento o acceso técnico es estrictamente necesario para el propósito legítimo de permitir el uso de un servicio específico explícitamente solicitado por el abonado o usuario, o con el único propósito de llevar a cabo la transmisión de una comunicación a través de una red de comunicaciones electrónicas.
Preferencias
El almacenamiento o acceso técnico es necesario para la finalidad legítima de almacenar preferencias no solicitadas por el abonado o usuario.
Estadísticas
El almacenamiento o acceso técnico que es utilizado exclusivamente con fines estadísticos.El almacenamiento o acceso técnico que se utiliza exclusivamente con fines estadísticos anónimos. Sin un requerimiento, el cumplimiento voluntario por parte de tu Proveedor de servicios de Internet, o los registros adicionales de un tercero, la información almacenada o recuperada sólo para este propósito no se puede utilizar para identificarte.
Marketing
El almacenamiento o acceso técnico es necesario para crear perfiles de usuario para enviar publicidad, o para rastrear al usuario en una web o en varias web con fines de marketing similares.
